Zhao FY, Zhang XM, Qian NS. Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy. World J Gastroenterol 2025; 31(10): 104429 [DOI: 10.3748/wjg.v31.i10.104429]
Corresponding Author of This Article
Nian-Song Qian, Chief Physician, MD, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100853, China. qianniansong1@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2025; 31(10): 104429 Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.104429
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
Fei-Yu Zhao, Xiao-Ming Zhang, Nian-Song Qian
Fei-Yu Zhao, Xiao-Ming Zhang, Nian-Song Qian, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100853, China
Author contributions: Zhao FY wrote the article; Zhang XM created the tables; Qian NS provided the writing ideas.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nian-Song Qian, Chief Physician, MD, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100853, China. qianniansong1@163.com
Received: December 19, 2024 Revised: January 13, 2025 Accepted: January 24, 2025 Published online: March 14, 2025 Processing time: 68 Days and 11 Hours
Abstract
In their study, Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and advanced hepatocellular carcinoma. The triple therapy, which integrates interventional therapy, targeted therapy, and immunotherapy, has emerged as a promising research focus in the treatment of liver cancer. Consequently, it is of utmost significance to select an appropriate combination of interventional therapy, targeted therapy, and immunotherapy for patients suffering from intermediate and advanced liver cancer.
Core Tip: Interventional therapy combined with immunotherapy and targeted therapy can significantly prolong the survival of intermediate and advanced hepatocellular carcinoma, but there are very few comparative studies studying the combination of different molecular targeted drugs, different immunotherapeutic drugs, and interventional therapy. Han et al studied the efficacy of lenvatinib or bevacizumab combined with sintilimab and interventional therapy, which can help clarify the efficacy of the combination of different drugs, providing a basis for clinicians to choose the correct treatment strategy for intermediate and advanced hepatocellular carcinoma.
